Characteristics of studies meeting inclusion criteria
| Study (year) | Population | Treatment frequency * | Duration of follow-up | DST based exclusion | MIRU-VNTR confirmed relapse | Total assigned to receive WHO standard regimen | Total eligible for analysis † | Total relapsed | Risk of relapse (%) |
| Oflotub14 12 (2014) | Adults with newly diagnosed, microbiologically confirmed, pulmonary tuberculosis | Daily | 24 months | RIF | No ‡ | 846 | 577 | 44 | 7.6 |
| REMoxTB12 13 (2014) | Adults with newly diagnosed, microbiologically confirmed, pulmonary tuberculosis | Daily | 18 months | RIF, FQN | Yes | 639 | 452 | 18 | 4 |
| Rifaquin13 14 (2014) | Adults with newly diagnosed, microbiologically confirmed, pulmonary tuberculosis | Daily | 18 months | RIF, INH, FQN, ETH | Yes | 275 | 160 | 5 | 3.1 |
*Daily defined as 5 or more days per week.
†Classified as either treatment success or relapse in per-protocol analysis set.
‡Composite outcome of relapse or reinfection.
DST, drug susceptibility testing; ETH, ethambutol; FQN, fluoroquinolone; INH, isoniazid; RIF, rifampin.